Journey Clinical

Journey Clinical is a New York-based neurotechnology company that has built a collaborative care platform enabling licensed psychotherapists to offer ketamine-assisted psychotherapy (KAP) within their existing practices. The company addresses a critical structural gap in the psychedelic medicine space by providing therapists with the medical infrastructure they need to prescribe and administer ketamine legally and safely. Their model combines clinical training, medical oversight, and prescribing support, allowing therapists to focus on the therapeutic relationship while Journey Clinical manages the regulatory and clinical complexities. This integrated approach effectively lowers the barrier to entry for mental health professionals seeking to adopt emerging psychedelic modalities.

Journey Clinical has secured $12 million in Series A funding, signaling strong investor confidence in its collaborative care model and the broader psychedelic-assisted therapy market. The company operates within a rapidly expanding landscape as ketamine remains one of the only legally available psychedelic-adjacent treatments for conditions such as treatment-resistant depression and PTSD. By positioning itself as an enablement layer for licensed therapists rather than a direct-to-consumer provider, Journey Clinical has carved out a distinctive and scalable market position. Their growth reflects increasing demand from mental health professionals who recognize the clinical value of psychedelic-assisted approaches but lack the infrastructure to deliver them independently.

Journey Clinical represents a meaningful development for the neurotech industry by demonstrating how platform-based models can accelerate the responsible adoption of psychedelic medicine at scale. Their work highlights the convergence of neuroscience, mental health care delivery, and regulatory navigation as defining challenges for the field. As the psychedelic therapy space moves toward broader clinical integration, companies like Journey Clinical provide the operational scaffolding necessary to translate emerging neuroscientific research into real-world therapeutic practice. Their model may serve as a template for how future psychedelic treatments, including MDMA and psilocybin, could be deployed through existing mental health infrastructure as regulatory pathways continue to evolve.